Invasive Fungal Infections Surveillance Initiative

This study has been completed.

Sponsor:

Collaborator:

Astellas Pharma US, Inc.

Information provided by (Responsible Party):

University of Pittsburgh

ClinicalTrials.gov Identifier:

NCT00177944

First received: September 13, 2005

Last updated: January 15, 2013

Last verified: January 2013

History of Changes

Purpose

The purpose of this study is to optimize the management of patients treated for invasive fungal infections by establishing a real-time, continuous clinical data base that will capture and monitor trends in the epidemiology, diagnosis, treatment and outcomes of invasive fungal infections; reflect routine clinical management of patients with invasive fungal infections in order to evaluate treatment and provide a rationale for future treatment paradigms; and allow physicians to assess adherence to institutional clinical practice guidelines, validate current standardized definitions for patients with invasive fungal infections and promote change where appropriate.

Condition
Fungal Infection


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Invasive Fungal Infections Surveillance Initiative

Resource links provided by NLM:

MedlinePlus related topics: Fungal Infections Molds

U.S. FDA Resources

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:

outcome after invasive fungal infection [ Time Frame: 60 days post infection ]
outcome after invasive fungal infection


Enrollment:	172
Study Start Date:	August 2005
Study Completion Date:	August 2012
Primary Completion Date:	August 2012 (Final data collection date for primary outcome measure)

Groups/Cohorts
patients with funal infections

Detailed Description:

Gender, height, weight, ethnicity, antifungal treatment, fungal colonization, laboratory results, past medical history, invasive fungal infection diagnosis, medications, outcomes

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

patients with funal infections

Criteria

Inclusion Criteria:

All patients with a diagnosis of proven or probable invasive fungal infection . This includes patients with proven or probable invasive mold infections as well as patients with proven candidemia.

Exclusion Criteria:

All patients with a diagnosis of possible invasive fungal infection . This includes patients with possible mold infections as well as patients with possible candidemia.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00177944

Locations


United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213

Sponsors and Collaborators

University of Pittsburgh

Astellas Pharma US, Inc.

Investigators


Principal Investigator:	Fernanda Silveira, MD	University of Pittsburgh

More Information


Responsible Party:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00177944 History of Changes
Other Study ID Numbers:	IRB # 0503062
Study First Received:	September 13, 2005
Last Updated:	January 15, 2013

Keywords provided by University of Pittsburgh:


invasive fungal infection

Additional relevant MeSH terms:


Infection Communicable Diseases Mycoses

ClinicalTrials.gov processed this record on August 16, 2017

To Top